Shire Development LLC - Recruiting N/A or older. - A Multicenter Open-Label Treatment Protocol to Observe the Safety of Replagalr (Agalsidase Alfa) Enzyme Replacement Therapy in Canadian Patients With Fabry Disease.
Amicus Therapeutics - Recruiting 18 years to 74 years. - Physician Initiated Request for Treatment Use of Migalastat Hydrochloride (GR181413A/AT1001), an Investigational Treatment for Individual Patients With Fabry Disease (MGM116188).
University of Rostock - Recruiting 18 years to 55 years. - Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation in Young Patients With Fabry Disease: An Epidemiological, International, Multicenter Prognosis Study.
Assistance Publique - Hpitaux de Paris - Recruiting 15 years or older. - A Multicenter, Phase 4, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Recombinant Alpha-Galactosidase A (Agalsidase Beta, FABRAZYME) in Heterozygous Females for Fabry Disease.